FDCP
VRTX icon

Foster Dykema Cabot & Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Foster Dykema Cabot & Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.9M Buy
58,233
+441
+0.8% +$195K 1.68% 16
2026
Q1 		$25.8M Sell
57,792
-552
-0.9% -$257K 1.64% 19
2025
Q4 		$26.5M Sell
58,344
-2,345
-4% -$1.01M 1.63% 19
2025
Q3 		$23.8M Sell
60,689
-234
-0.4% -$97.8K 1.56% 22
2025
Q2 		$27.1M Sell
60,923
-532
-0.9% -$245K 1.91% 19
2025
Q1 		$29.8M Buy
61,455
+591
+1% +$275K 2.39% 14
2024
Q4 		$24.5M Buy
60,864
+1,094
+2% +$507K 1.91% 19
2024
Q3 		$27.8M Sell
59,770
-205
-0.3% -$98.5K 2.33% 13
2024
Q2 		$28.1M Buy
59,975
+250
+0.4% +$109K 2.51% 11
2024
Q1 		$25M Buy
59,725
+2,299
+4% +$972K 2.33% 16
2023
Q4 		$23.4M Buy
+57,426
New +$21.2M 2.48% 10

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Foster Dykema Cabot & Partners's VRTX Position: Q2 2026 in Review

Foster Dykema Cabot & Partners increased its Vertex Pharmaceuticals (VRTX) stake by 0.76% in Q2 2026, buying an estimated $195K and bringing the position to 58,233 shares worth $28.9M. The position accounts for 1.68% of the portfolio, ranked #16.

Foster Dykema Cabot & Partners first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $29.8M in Q1 2025. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Foster Dykema Cabot & Partners held 58,233 shares of Vertex Pharmaceuticals worth $28.9M as of Q2 2026.
  • Foster Dykema Cabot & Partners bought 441 Vertex Pharmaceuticals shares in Q2 2026, an estimated $195K.
  • Vertex Pharmaceuticals made up 1.68% of Foster Dykema Cabot & Partners's portfolio in Q2 2026, its #16 holding.
  • Foster Dykema Cabot & Partners first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Foster Dykema Cabot & Partners's Vertex Pharmaceuticals position peaked at $29.8M in Q1 2025.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Foster Dykema Cabot & Partners's 13F filing for Q2 2026, filed 11 Aug 2026.